Analyzing the Financial Health of Biotech Companies

LAS VEGAS, August 17, 2017 /PRNewswire/ --

The business and technology behind the biotechnology industry is multifaceted and uncertain. This makes analyzing a biotech company's future success a challenging job. What makes this task even more difficult is the fact that many biotech companies are in different stages of development with no earnings or revenue, and little cash flow. Traditional financial analysis are not applicable as these numbers don't accurately represent where the company is going. Many companies are releasing their Q2 financial results this time of year. When viewing the numbers you should also take into account the qualitative data, not just the numbers.

Since financial results can be deceiving based on a pure numbers standpoint due to the nature of biotechnology, it's vital to consider the following points when checking their financial results:

• Number of products and pipelines: a company should be developing a technology platform with numerous treatment opportunities and not just one.
• Number of patents: this is important to know so that you can identify which possess patents to protect their technology and innovation.
• Successful Research and Development (R&D) history: a sign of company success is the ability to develop cost-effective drugs that represent breakthrough therapies, following the R&D processes for a company is vital.

Some such companies include: Propanc Biopharma Inc. (OTC: PPCB), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), Ziopharm Oncology Inc. (NASDAQ: ZIOP), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP).

Propanc Biopharma Inc. (OTCQB: PPCB) is a biotech company in great financial health. They are a leading biotech company focused on the development of new and proprietary treatments for cancer patients. Their lead product, PRP, is patented across several international countries after their filing of a Patent Cooperation Treaty in April of this year. This product pipeline is diverse and aims to prevent aims to prevent tumor recurrence and metastasis from solid tumors, the main cause of patient death from cancer. The company has recently focused its efforts on Chemistry, Manufacturing and Control (CMC) activities in order to produce the Investigational Medicinal Product (IMP) for PRP, to be used for the upcoming First-In-Human studies. As their product continues to see success in securing patents and furthering their R&D, PPCB is positioning itself for great financial success.

Once their Q2 financial results are released, it will be important to keep in mind the qualitative data on PPCB while analyzing the numbers.

BIOTECH AND PHARMA INDUSTRY FINANCIAL HIGHLIGHTS… 

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Market Cap: $229.99M, current share price: 2.72 

CPRX develops and commercializes therapies for patients with rare diseases. They develop drugs that target neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. They released their Q2 financial results this past week, to listen to the replay of the conference call you can access it by using this link: https://www.investornetwork.com/company/23809.

Ziopharm Oncology Inc. (NASDAQ: ZIOP)

Market Cap: $774.88M, current share price: 5.51 

ZIOP is a company developing chimeric antigen receptor (CAR) T cell (CAR⁺ T), T-cell receptor (TCR) T cell (TCR⁺ T), and natural killer (NK) adoptive cell-based therapies. Just last month they reported their Q2 financial results. They reported a loss of $12.9 million in Q2 but claim advancements in R&D and recent FDA approvals will get their value back up.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

Market Cap: $163.212M, current share price: 2.95 

BDSI is a pharmaceutical company specializing in pain and addiction and released their Q2 financial results last week. They reported their net revenue for Q2 was approximately $8.7 million, compared to $29.5 million in the first quarter of 2017, and $5.0 million in the second quarter of last year.

Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP)    

Market Cap: $308.48M, current share price: 13.17 

AQXP is a clinical-stage pharmaceutical company aimed at discovering and developing targeted therapeutics in disease areas of both immuno-oncology and inflammation. They reported a loss of 13.8M at the end of Q2.

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link: http://microcapspeculators.com/disclaimer/

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
editor@financialnewsmedia.co
+1-(954)-345-0611